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The capacity of embryonic stem (ES) cells for virtually unlimited self renewal and differentiation has opened up the
prospect of widespread applications in biomedical research and regenerative medicine. The use of these cells would
overcome the problems of donor tissue shortage and implant rejection, if the cells are made immunocompatible with
the recipient. Since the derivation in 1998 of human ES cell lines from preimplantation embryos, considerable research
is centered on their biology, on how differentiation can be encouraged toward particular cell lineages, and also on the
means to enrich and purify derivative cell types. In addition, ES cells may be used as an in vitro system not only to
study cell differentiation but also to evaluate the effects of new drugs and the identiﬁcation of genes as potential
therapeutic targets. This review will summarize what is known about animal and human ES cells with particular
emphasis on their application in four animal models of human diseases. Present studies of mouse ES cell
transplantation reveal encouraging results but also technical barriers that have to be overcome before clinical trials
can be considered.
CELL therapy is an increasingly attractive concept inmodern transplantation medicine. For many clinical
situations, replacement of lost cells would be the ideal treat-
ment. These situations include age-related diseases with
progressive cell loss (various types of congestive heart fail-
ure, brain degenerative diseases, and sarcopenia), traumatic
tissue loss, and iatrogenic destruction of cells (e.g., bone
marrow transplantation). In many cases, however, the de-
velopment of cell therapeutic treatment approaches is
hampered by an increasing lack of donors or by the lack
of cells that are suitable for transplantation.
A possible solution to this problem lies in xenografts
(i.e., transplantation of tissues of animal origin); however,
for several reasons (ethical, immunological, infectious dis-
eases), this approach has a limited usefulness. A way out of
this problem would be the differentiation of embryonic stem
(ES) cells into specific cell types and tissues. In fact, recent
developments in the field of stem cell biology and, in
particular, of human ES cells have generated hope that this
lack of suitable cells can be overcome.
Isolated 4 years ago from preimplantation embryos by
Thomson et al. (1), human embryonic stem (hES) cells have
the capacity to differentiate into virtually all of the cell types
building our body. These cells therefore hold the promise of
forming any desired tissue in culture that could be used
to treat a wide variety of conditions where age, disease, or
trauma has led to tissue damage or dysfunction. This radical
new approach of disease treatment would overcome the
problems of donor tissue shortage and, by making the cells
immunocompatible with the recipient, implant rejection.
This review focuses on what is known so far about ES
cells, with particular emphasis on the progress made in the
characterization of ES cells from mouse and humans, as
well as on the present achievements of ES cell-based ther-
apies in animal models of human diseases.
THE WORLD oF STEM CELLS
What are embryonic stem cells and what makes them
different from other cells? How do they regulate their self-
renewal and how they specialize into a given type? Can
we encourage their differentiation towards specific cell line-
ages suitable for cell therapies? These are some of the cru-
cial questions that scientists all over the world are trying to
elucidate.
Stem cells are commonly defined as undifferentiated cells
that can proliferate and have the capacity of both self-
renewal and differentiation to one or more types of
specialized cells. They can be found in the embryo and
fetus, and also several organs of the adult human body, with
the degree of potentialities commonly decreasing as cells
commit to a lineage and specialize. The most promising,
and also the most controversial, are embryonic stem cells,
which are present in the very early embryo at the stage of the
blastocyst, about 1 week after fertilization. They constitute
the inner cell mass, a hollow ball of undifferentiated cells
(which will form the entire embryo), and are surrounded
by a shell of cells (the trophoblast, which will form the
placenta). When removed from the blastocyst, ES cells can
be cultured and propagated indefinitely in an undifferenti-
ated pluripotent state. The isolation of ES cells at the
blastocyst stage is imperative, since from this stage onward
different populations of cells, when provided with the
appropriate signals, begin to specialize and display specific
functions [for review see (2)].
The successful derivation of murine ES cells from the
inner cell mass of mouse blastocysts was achieved in 1981,
allowing culture conditions to be defined to support their
unlimited propagation (3,4). Murine ES cells remain un-
differentiated when grown in the presence of leukemia
inhibitory factor (LIF) and, for some cell lines, cultured on
murine embryonic fibroblasts (MEF) as feeder cells (5,6)
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(see Figure 1). These cells were soon shown to be pluri-
potent, i.e., capable of forming all mature cell phenotypes
derived from the three embryonic layers: endoderm, ecto-
derm, and mesoderm (2). In fact, when LIF or feeder cells
are withdrawn, most types of ES cells differentiate sponta-
neously to form aggregates called embryoid bodies. These
tridimentional cell–cell contacts allow the formation of
heterogeneous cultures of differentiated cell types including
cardiomyocytes (7,8), hematopoietic cells (9,10), endo-
thelial cells (11–13), neurons (14,15), skeletalmuscle (16,17),
chondrocytes (18), adipocytes (19), liver (20), and pancreatic
islets (21).
HUMAN ES CELLS
The first nonhuman primate embryonic stem cells were
described in 1995, maintained in culture for more than a
year, while retaining their pluripotency, self-renewing capa-
city, and their normal karyotype (22). It was only in 1998
that Thomson et al. reported the first successful derivation
and propagation of human ES (hES) cells derived from the
inner cell mass of in vitro-fertilized early blastocysts (1).
Like the primate ES cells derived earlier, hES are pluri-
potent, self-renewing (remaining in the undifferentiated
state without losing pluripotency), telomerase positive (an
enzyme that confers an unlimited replicative capacity), and
have a normal karyotype.
Human pluripotent stem cells, called human embryonic
germ (hEG), also could be derived from fetal material ob-
tained frommedically terminated pregnancies (23). Although
obtained from different sources by different laboratory
processes, both hES and hEG cells have been demonstrated
to be pluripotent (capable of forming all cells and tissues in
the body) (24). Several lines of hES cells have been
produced, including some that were clonally derived (25).
Human ES cells show several morphological and be-
havioral differences from murine ES cells: They grow more
slowly and tend to form flat rather than spherical colonies
(25,26). Moreover, LIF does not have the same effect on
human ES cells as compared to mouse ES cells: To remain
undifferentiated, hES require culture on MEF feeder layers
in the presence of basic fibroblast growth factor (bFGF) (3,4),
on Matrigel, or laminin in MEF-conditioned medium (27).
There is a rapidly increasing number of reports describ-
ing hES cell differentiation into neurons (28), endothelium
(29,30), hematopoietic cells (31), functionally active pan-
creatic cells (32), and beating cardiomyocytes (26,33,34).
Current research focuses on how to coax ES cell differ-
entiation to a desired lineage, derive highly purified cell
populations lacking any carcinogenic potential, and per-
form cell implantation in a form that will replace or
augment the function of diseased or degenerating tissues
(26,35).
ROLE oF EXTRACELLULAR FACTORS
Studies of gene expression during mammalian embryonic
development have led to the identification of some factors
that preferentially induce a specific lineage differentiation
(36,37). As with murine ES cells, modification of the culture
medium in which human ES cells are grown can encourage
the differentiation of certain lineages (36). For example, en-
riched populations of proliferating neural progenitors have
been obtained by supplementation of the culture medium
with specific growth factors (38,39). The temporal interplay
between growth factors like FGFs, EGF, Shh, and BMPs
can regulate the differentiation of neurons and glia in tissue
culture (40,41).
Providing specific local influences through coculture with
mature cells can also encourage the formation of a particular
lineage. For example, ES cells grown with bone marrow cells
or yolk sac endothelium form hematopoietic precursors (31).
On the other hand, upon injury, several organs are able
to release factors that activate repairing mechanisms and
induce resident stem cells, partially committed but not fully
differentiated, to further progress and replace damaged or
dead cells with new units. Well-known examples are bone
marrow, skin, liver, and skeletal muscle. This does not seem
to be the case with the brain, which despite possessing a
population of neural stem cells, does not seem to be able to
activate enough brain stem cells upon major injury or cell
loss (e.g., brain stroke, Parkinson’s disease, Alzheimer’s
disease) (42). It is therefore conceivable that a healthy organ
may not be capable of locally releasing cues to prime the
implanted cells, while damaged tissue may be activated to
release important molecules for both the recruitment of
resident adult stem cells when available or distant stem
cells from other compartments (i.e., the bone marrow). The
identification of those factors will therefore be fundamental
to optimally initiate in vitro a suited differentiation that
could be pursued in situ. One could also envisage
genetically inducing the implanted cells to transiently
secrete factors favoring a neovascularization, for example,
via the insertion of vascular endothelial growth factor
(VEGF) transgene under the control of an inducible
promoter. This would allow optimal integration in the
recipient organ and avoid the long-term deleterious effects
of uncontrolled long-term secretion (43–45).
TECHNICAL OBSTACLES TO THE
CLINICAL USE oF ES CELLS
Selection of Suitable Cell Type
For clinical development, it is first necessary to develop
methods to purify populations of specific cell types from a
complex structure of differentiating stem cells. The removal
of undifferentiated stem cells from the cultures prior to clin-
ical use is critical to avoid the risk of teratoma formation.
So far, none of the approaches used on murine ES cells
can give 100% yield of cells with the required phenotype.
Methods such as FACS (fluorescence-activated cell sorting)
or MACS (magnetic-activated cell sorting) allow such puri-
fication using fluorescence or magnetic microbead-tagged
antibodies recognizing a surfacemarker selective for a desired
cell lineage. If this is not available, ES cells can be transduced
with a lineage-specific promoter that can drive the expres-
sion of a marker, such as green fluorescent protein (46) or an
antibiotic resistance gene, as illustrated in Figure 2 (47).
This allows for preferential selection of cell subpopulations
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Figure 1. Examples of mouse embryonic stem (ES) cell clones, which are propagated in an undifferentiated state by culturing them over mitomycin-inactivated
mouse embryonic fibroblasts as feeder cells and in the presence of the cytokine LIF (leukemia inhibitory factor) (panel a). Some cell lines are feeder cell-independent
such as the CGR8 line (49) (panel b). Every 2 days, cells are dissociated by trypsinization. Undifferentiated ES cells can be expanded in the presence of LIF, or their
differentiation can be initiated by removing LIF and by forming three-dimensional structures called embryoid bodies (EB) containing the three embryonic derivatives.
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defined by the cell type specificity of the promoter utilized.
This type of approach has been used to select neural and
cardiomyocyte phenotypes (48–50).
Immunohistocompatibility
A barrier to overcome is to avoid the rejection of the
implanted cells by the recipient. In fact, immunosuppres-
sive drugs are associated with many highly unpleasant side
effects, and such a treatment would not represent an opti-
mally acceptable option. Interestingly, ES cells seem to
express less immune-related cell surface proteins (e.g., class
I products of the major histocompatibility complex) (51).
Drukker et al. (52) addressed the graft rejection issue of
cells derived from hES cells by showing that both un-
differentiated or differentiated hES express no major histo-
compatibility complex (MHC)-II proteins or human leukocyte
antigen (HLA)-Gandvery low levels ofMHCclass I (MHC-I)
proteins on their surface. MHC-I molecules, however, may
be dramatically and rapidly induced by treating the cells
with interferons. If a similar phenomenon occurs after trans-
plantation, allogeneic human ES cells might be rejected by
cytotoxic T lymphocytes.
It is likely that the problem of rejection of grafted human
ES-derived cells could be overcome (or at least minimized)
by establishing ‘‘histocompatibility banks’’ of hES with com-
pletely HLA-typed ES cell clones derived using good
manufacture practice (GMP) protocols. Ideally, if large num-
bers of cell lines from genetically diverse populations can
be maintained, this would provide isotype-matching cells
for virtually any patient.
Other possibilities include means of reducing or abolish-
ing cell immunogenicity. ES cells, unlike adult cells, can
be easily modified genetically by, for example, inserting
immunosuppressive molecules such as Fas ligand, or re-
moving immunoactive proteins such as B7 antigens (53).
Alternatively, one could delete the foreign MHC genes or
insert genes coding for the recipient’s MHC (54).
Ultimately, neoplastic growth or immunopathology could
be suppressed by introducing into ES cells before implanta-
tion suicide genes that permit their ablation in case of mis-
behavior. For example, herpes thymidine kinase sensitizes
mouse ES cells to destruction by the guanosine analog gan-
cyclovir (55).
Total immunocompatibility of tissue engineered from
human ES cells (56–58) could be theoretically obtained
by somatic nuclear transfer (also defined as therapeutical
cloning). This procedure uses the transfer of a somatic cell
nucleus from an individual into an enucleated oocyte (59,60).
Such an oocyte would then undergo embryonic develop-
ment to the blastocyst stage prior to isolation from the inner
cell mass of hES cells that would be genetically matched
to the tissues of the nucleus donor. So far, one group has
claimed the nuclear transfer derivation of a human embryo
up to only a six-cell stage (61,62), but the success of this
result is still questioned. Clearly, this procedure of somatic
nuclear transfer is still highly problematic from an ethical
and practical point of view.
HOW FAR ARE WE FROM CLINICAL APPLICATIONS
USING ES CELLS?
Presently, only allogeneic or matched donor-derived adult
stem cells have been used in human cell-grafting therapies.
The best known and established example is bone marrow
transplantation for the treatment of leukemia and, recently,
transplantation of hematopoietic stem cells derived from
umbilical cord blood. However, there are still problems with
accessibility, low frequency (e.g., in bone marrow there is
roughly 1 stem cell per 100,000 cells), restricted differen-
tiation potential, and poor growth, which are limiting their
applicability to tissue engineering (63). Nevertheless, there
are several ongoing phase I trials using bone marrow and
skeletal satellite cells for the treatment of human heart fail-
ure (64), despite unconvincing or contradictory evidence for
a correct in situ transdifferentiation of these adult stem cells
implanted in the heart of animal models (65).
So far, there are few examples of ES cell-based ther-
apy using animal models of diseases that have provided
encouraging and promising results. As illustrated in Figure 3,
these are (a) rat model of spinal cord injury, (b) mouse model
of Parkinson’s disease, (c) myocardial infarction (MI) in mice
and rats, and (d) diabetes in mouse. We will describe them
and discuss the limitations of the present achievements.
Figure 2. Possible methods for the selection of a suited cell lineage include the
insertion into embryonic stem (ES) cells of transgenes (i.e., fluorescence reporter
genes or antibiotic resistance genes) under the control of tissue-specific
promoters. Upon differentiation, the expression of the transgene is dictated by
the tissue-specific promoter, allowing the selection of the desired cell type, i.e.,
using cell sorting or cell recovery after antibiotic treatment. [Adapted from
Strom et al. (95).]
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Spinal Cord Injury
The absence of spontaneous axonal regeneration in the
adult mammalian central nervous system causes devastating
functional consequences in patients with spinal cord in-
juries. During the past decade, several attempts have been
made to find a strategy to repair injured spinal cords in ex-
perimental animals, which could provide a novel therapeutic
approach in humans. Very interesting results have been
achieved recently in a rat model of spinal cord injury (66).
When a heterogeneous population of differentiating ES cells
(i.e., derived from embryoid bodies cultured 4 days without,
then 4 days with, retinoic acid) were transplanted into in-
jured spinal cords, they were able to survive, migrate, and dif-
ferentiate, allowing a neurological improvement in treated
animals, which recovered leg movement, as compared to
paralyzed sham-treated controls. More recently, Wichterle
et al. showed that developmentally relevant signaling factors
can induce mouse ES cells to differentiate into functional
motoneurons able to repopulate the embryonic spinal cord,
extend axons, and form synapses with target muscles (67).
Furthermore, it has been shown that ES cells, when trans-
planted into adult rat spinal cord after chemical demyelina-
tion or in myelin-deficient mutant mice, differentiated into
mature oligodendrocytes, produced myelin, and myelinated
host axons (68).
Parkinson’s Disease
Parkinson’s disease (PD) is a common degenerative
disorder that affects more than 2% of the population over
65 years of age. PD is characterized by the selective and
gradual loss of dopaminergic neurons in the substantia nigra
of the midbrain with a subsequent reduction in striatal dop-
amine. The loss of this group of neurons is responsible for
most PD symptoms (i.e., tremor, rigidity, and hypokinesia).
PD has been treated with grafts of fetal cells, but the
limited access of these cells and their poor survival restrict
wider application of this approach. ES cells may be
particularly valuable for circumventing this problem, as
they can proliferate and maintain their developmental po-
tential in culture. Dopaminergic neurons have been effi-
ciently derived from ES cells in vitro (69). Bjorklund et al.
(70) have transplanted a very small number of partially
differentiated mouse ES cells derived from embryoid bodies
into a rat model of PD, and have shown that at least some
of them become dopamine neurons in the striatal regions
where the endogenous neurons were previously destroyed.
This allowed the Parkinson symptoms to reverse in 50% of
the animals, while only 25% of them developed brain
tumors (70,71). If a large number of ES cells are implanted
into the brain, they grow into every cell type and form
teratomas in all cases, eventually killing their host (72).
More recently, Kim et al. (73) have characterized the electro-
physiological and behavioral properties of highly enriched
populations of mouse ES-derived midbrain neural stem cells,
able to functionally integrate into host tissue and improve
symptoms in a rodent model of PD. The use of neuron-
selective media were reported to increase the fraction of
neuronal cells, and this type of optimization may be funda-
mental for the safe production of selected phenotypes (69).
Whether a similar outcome will soon be demonstrated for
hES cells will depend on the development of safe strategies
that will allow immunotolerance and avoid tumorigenic risks.
Figure 3. Examples of applications of mouse embryonic stem cells to repair or replace diseased tissues in animal models of human diseases.
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Myocardial Infarction and Heart Failure
Chronic congestive heart failure (CHF) is a common
consequence of heart muscle or valve damage and represents
a major cause of cardiovascular morbidity and mortality in
developed countries. When heart muscle is damaged by
injury or decreased blood flow (ischemia), functional con-
tracting cardiomyocytes are replaced with nonfunctional
scar tissue. In fact, cardiomyocyte withdrawal from the cell
cycle in the early neonatal period renders the adult heart
incapable to regenerate after injury. Therefore, the use of a
cell therapy approach to replace lost cardiomyocytes with
new engraftable ones would represent an invaluable, low-
invasiveness technique for the treatment of heart failure as
an alternative to whole heart transplantation.
The way in which hES cells could be used to treat heart
disease has already been tested in mice and rats. Mouse ES
cells, when cultivated as embryoid bodies, are able to dif-
ferentiate in vitro into cardiomyocytes of ventricle-, atrium-,
and pacemaker-like cell types characterized by develop-
mentally controlled expression of cardiac-specific genes,
structural proteins, sarcomeric proteins (74,75), and ion
channels (8,76,77). Since only approximately 5% of the cell
population within embryoid bodies are cardiomyocytes,
the selection of an enriched culture of cardiomyocytes has
required genetic manipulation (47,49,50). Clearly, the purity
of differentiated ES-derived cardiomyocyte culture is a key
issue to avoid the potential formation of teratomas, which
would disrupting heart contractility.
Klug et al. were the first to show that ES-derived car-
diomyocytes, selected using an antibiotic selection cassette
(Figure 2) and injected into the hearts of dystrophin-
deficient MDX mice, were able to repopulate the myocardial
tissue and integrate with host myocardial tissue (47).
Enriched populations of cardiomyocytes were obtained by
introducing into ES cells a neomycin resistance gene under
the control of the a-cardiac myosin heavy chain promoter.
On differentiation, only cardiac-committed cells expressing
the antibiotic resistance gene can survive when treated with
neomycin. Similarly, cardiomyocytes with a ventricular
phenotype have been selected using the ventricular-specific
myosin light chain isoform 2v promoter controlling the
expression of green fluorescent protein (49,50). So far, how-
ever, no study has investigated the engraftment of specific
subpopulations of ES-derived cardiomyocytes, such as
ventricular, atrial, or pacemaker cells. Whether these ap-
proaches can generate sufficient numbers of cardiac cells
suited for myocardial repair in vivo remains to be established.
Ideally, understanding how to control cardiomyocyte differ-
entiationwouldmaximize proliferation of cardiac progenitors
cells in culture while impeding their terminal differentiation,
which should be undergone after transplantation.
Several animal models of MI using coronary ligation
in rats or cryoinjury in mice have been used to test the
implantation of fetal-, embryo-, or ES-derived cardiomyo-
cytes by direct injection into heart muscle (78–81). Li et al.
demonstrated that transplanted fetal cardiomyocytes could
integrate cryoinjured cardiac tissue and improve heart func-
tion (82,83). Transplantation of stage E12 to E15 embryonic
cardiomyocytes into MI or cryoinjured hearts attenuated left
ventricular dilatation, infarct thinning, and myocardial
dysfunction (79,84). Recently, Min et al. engrafted, 30
minutes after MI in rats, ES-derived cardiomyocytes
manually dissected from beating embryoid bodies in culture.
Although implanted cells survived and integrated the
myocardium, which was associated with considerable im-
provement of global cardiac function, still many grafts
remained isolated and did not differentiate into an adult
phenotype (81).
The results published so far indicate that ES cell
transplantation is a feasible approach to improve ventricular
function in the infarcted failing heart. However, despite
encouraging beneficial effects on heart function and
remodeling, the mechanism behind these results remains
to be demonstrated. Benefits may be associated with en-
hanced angiogenesis via the release of angiogenic factors
such as VEGF. Several key issues still need to be addres-
sed including the extent to which cell engraftment affects
cardiac function actively (i.e., by increasing contractility via
functional integration or via the secretion of growth factors)
or passively (i.e., by limiting infarct expansion and re-
modeling). Importantly, the possibility that some ES cells
not committed to cardiac lineage could form deleterious
teratomas with time has not yet been ruled out.
Diabetes
Diabetes results from abnormal function of pancreatic b-
cells, which are responsible for insulin synthesis, storage,
and release. Lack or defect of insulin produces diabetes
mellitus, a devastating disease suffered by 150 million
people in the world. Transplantation of insulin-producing
cells could be a cure for type 1 and some cases of type 2
diabetes.
Mouse and human ES cells can produce insulin-secreting
cells in culture (32,85). Lumelsky et al. showed that mouse
ES cells can coordinately differentiate into multiple types of
pancreatic endocrine cells that self-assemble into structures
resembling pancreatic islets. When implanted subcutane-
ously in diabetic mice, these cells, although able to vascu-
larize and remain immunoreactive to insulin, could not
reverse high blood sugar levels in mice with symptoms of
diabetes (21). This may not be surprising considering the
inappropriate site of implantation and the insufficient
amount of insulin produced. Nonetheless, grafted animals
were able to maintain their body weight and survive for
longer periods.
Implantable b-cells are likely to require protection from
recurring autoimmunity. This protection might take the form
of tolerization, cell encapsulation, or cell engineering with
immunoprotective genes. New insights into endocrine pan-
creas development using hES are leading to manipulation of
progenitor-cell fate towards the b-cell phenotype of insulin
production, storage, and regulated secretion, which, in turn,
could lead to widespread cell replacement therapy for type 1
diabetes (86).
CONCLUSIONS
The derivation of hES cells is a fundamental discovery
that holds promise for three major areas of biomedicine: (a)
transplantation medicine, (b) pharmaceutical research and
development, and (c) human developmental biology.
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Transplantation Medicine
The availability of hES cells opens extraordinary
opportunities for tissue transplantation. Examples of cells
for transplantation therapies include heart muscle cells for
use in repairing the tissue damage inflicted by heart attacks,
blood-forming cells for use in bone marrow transplantation
procedures for cancer patients, and nerve cells for use in
treating patients with spinal cord injury, stroke, Parkinson’s
or Alzheimer’s diseases, and diabetes. Frailty is a major
problem in geriatric medicine (87–89). Its pathogenesis
involves neuronal and muscle cell failure as well as decreased
cardiovascular function (90,91). The availability of hES cells
represents a tremendous potential to reverse frailty and pre-
vent functional decline.
Pharmaceutical Research and Development
Human embryonic stem cells also represent a new
technology for pharmaceutical research and development.
Until now, the only cell lines available for this work were
either animal or abnormal transformed human cells. Per-
manent, stable sources for normal human differentiated cells
may be developed for drug screening and testing, drug
toxicology studies, as well as new drug target identification
(92–94). In addition, hES cells may also allow the creation
of in vivo models of human disease for drug development as
a superior alternative to current mouse models.
Human Developmental Biology
Finally, unraveling the biology of hES cells as they
differentiate into functional cell types in vitro offers a unique
platform to understand the mechanisms of human embry-
onic development, tissue differentiation, and repair. Until
now, early genetic events in human embryology have been
largely inaccessible to direct observation. Research with
hES cells may lead to the discovery of novel genes that
fundamentally control tissue differentiation, and may
facilitate a molecular understanding of how specific human
tissues and organs develop without conducting research on
human embryos or fetuses. These gene products could result
in the development of therapeutic drugs and proteins with
potential applications in wound healing, stroke, heart attack,
spinal cord injury, and brain degenerative diseases.
Successful use of any stem cell-based therapy will event-
ually depend on our ability to isolate specific cell types in
large numbers that will differentiate to a fully functional
state, as well as on the challenging demonstration of their
in vivo function. To this end, it is crucial to pursue basic
research on human ES cell biology to ensure better under-
standing of basic principles and what genes and proteins are
essential for hES developmental progression. This compre-
hension does not only specifically involve the transplantation
of ES cell-derived cells but will also help the development
of new therapeutic strategies to improve the transdifferentia-
tion and expansion of adult stem cells, such as umbilical
cord blood cells or bone marrow cells. Many hurdles
(not only technical but also ethical) have to be cleared
before the research reaches a point where clinical trials can
begin.
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